We are live on
!
Find out more
BC
Birchview Capital Portfolio holdings
AUM
$176M
1-Year Est. Return
95.04%
This Fund
S&P 500
This Quarter
Est. Return
+9.57%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$190M
AUM Growth
+$18.1M
(+11%)
Cap. Flow
+$4.61M
Cap. Flow
% of AUM
2.42%
Top 10 Holdings %
Top 10 Hldgs %
89.79%
Holding
38
New
5
Increased
4
Reduced
5
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$3.14M |
| 2 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$1.17M |
| 3 |
Xencor
XNCR
|
+$789K |
| 4 |
OMED
OncoMed Pharmaceuticals, Inc.
OMED
|
+$563K |
| 5 |
Cerus
CERS
|
+$425K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
|
+$1.1M |
| 2 |
TRNX
TORNIER N V SHARES (NLD)
TRNX
|
+$481K |
| 3 |
QTNT
Quotient Limited Ordinary Shares
QTNT
|
+$340K |
| 4 |
Accuray
ARAY
|
+$183K |
| 5 |
PTC Therapeutics
PTCT
|
+$183K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.14% |
| 2 | Consumer Staples | 4.01% |
| 3 | Energy | 3.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Biogen
BIIB
$30B
| $591K | 0.31% |
1,400
| – | – |
|
27
Puma Biotechnology
PBYI
$416M
| $508K | 0.27% |
2,150
| – | – |
|
|
MACK
28
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $503K | 0.26% |
5,376
| – | – |
|
|
PXD
29
DELISTED
Pioneer Natural Resource Co.
PXD
| $491K | 0.26% |
3,000
| – | – |
|
|
ROKA
30
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
| $487K | 0.26% |
15,231
+6,641
| +77% | +$273K |
|
|
31
Cerus
CERS
$647M
| $346K | 0.18% |
+83,000
| New | +$425K |
|
|
RPTP
32
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
| $326K | 0.17% |
+30,000
| New | +$306K |
|
33
Agios Pharmaceuticals
AGIO
$2.38B
| $321K | 0.17% |
3,400
| – | – |
|
|
QTNT
34
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $309K | 0.16% |
455
-538
| -54% | -$340K |
|
|
PQUE
35
DELISTED
PETROQUEST ENERGY INC (DE)
PQUE
| $281K | 0.15% |
122,050
| – | – |
|
|
NXTM
36
DELISTED
NxStage Medical Inc.
NXTM
| $254K | 0.13% |
14,700
| – | – |
|
37
Coherus Oncology
CHRS
$217M
| $229K | 0.12% |
+7,500
| New | +$194K |
|
38
InspireMD
NSPR
$33.1M
| – | – |
0
| – | – |
|
Similar funds
RWA
BAM
TIM
TFCM
FPW
LWM
PFA
DAM
Birchview Capital's Q1 2015 Portfolio in Review
As of Q1 2015, Birchview Capital held 38 positions worth $190M, up 11% from $172M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Birchview Capital's Q1 2015 filing shows 5 new, 4 increased and 5 reduced positions. Its largest new stake was Aegerion Pharmaceuticals: 46,000 shares worth $1.2M. The largest sale was AUSPEX PHARMACEUTICALS INC COM STK (DE), an estimated $1.1M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier, followed by Consumer Staples and Energy.
- Birchview Capital's largest Q1 2015 buy was Aegerion Pharmaceuticals: 46,000 shares worth $1.2M.
- Birchview Capital added most to Celgene Corp in Q1 2015, an estimated $3.14M increase.
- Birchview Capital's biggest Q1 2015 reduction was AUSPEX PHARMACEUTICALS INC COM STK (DE), cutting an estimated $1.1M.
- Birchview Capital's ten largest holdings make up 90% of its $190M portfolio in Q1 2015.
- Birchview Capital opened 5 new positions and closed 0 in Q1 2015.
- Birchview Capital's portfolio value rose 11% quarter-over-quarter to $190M.
Based on Birchview Capital's 13F filing for Q1 2015, filed 24 Apr 2015.